Revance Therapeutics logo

Revance Therapeutics Funding & Investors

Revance Therapeutics, Inc. produces biopharmaceutical products. The Company develops drug delivery and treatments for dermatology and aesthetic medicine. Revance Therapeutics serves patients and doctors throughout the United States.

revance.com

Total Amount Raised: $1,579,526,016

Revance Therapeutics Funding Rounds

  • Post Ipo Equity

    $200,000,000

  • Post Ipo Debt

    $300,000,000

    Post Ipo Debt Investors

    Athyrium Capital Management
  • Post Ipo Debt

    $250,000,000

  • Post Ipo Equity

    $110,500,000

  • Post Ipo Equity

    $115,000,000

  • Post Ipo Equity

    $167,100,000

    Post Ipo Equity Investors

    Cowen Investment Management
  • Post Ipo Equity

    $126,000,000

  • Post Ipo Equity

    $131,300,000

  • Series Unknown

    $10,000,000

  • Series E

    $33,000,000

    Series E Investors

    Delphi Ventures
    Essex Woodlands
    NovaQuest Capital Management
  • Series D

    $45,000,000

    Series D Investors

    CNF Investments
    Essex Capital
    Vivo Capital
    Pac-Link
    Palo Alto Investors
    Essex Woodlands
    Technology Partners
    Shepherd Ventures
    NovaQuest Capital Management
  • Series D

    $25,620,000

    Series D Investors

    EDBI
    Vivo Capital
    Pac-Link
    Palo Alto Investors
    Essex Woodlands
    Technology Partners
    Shepherd Ventures
    Bio*One Capital
  • Debt Financing

    $8,000,000

    Debt Financing Investors

    Leader Ventures
    Horizon Technology Finance
  • Series C

    $43,200,000

    Series C Investors

    Medicis Pharmaceutical
    Vivo Capital
    Palo Alto Investors
    Essex Woodlands
    Technology Partners
    Shepherd Ventures
  • Series B

    $13,000,000

    Series B Investors

    Vivo Capital
    Essex Woodlands
    Technology Partners
  • Series A

    $1,806,000

  • IPO

    Unknown

Funding info provided by Diffbot.